#USA #New York #Pomerantz #REGENXBIO #RGNX

Pomerantz Law Firm Issues Class Action Alert for REGENXBIO Investors

The Pomerantz Law Firm has issued an important notice to investors regarding a class action lawsuit filed against REGENXBIO Inc. (NASDAQ: RGNX). This development is particularly crucial for those who have suffered losses on their investments in the company. Investors are being encouraged to come forward and potentially join this class action to seek justice and recover their losses.

Background of the Class Action Lawsuit

The lawsuit alleges that REGENXBIO and certain key officers or directors may have engaged in securities fraud or other illegal business practices. Investors who purchased or acquired securities of REGENXBIO during the designated class period are advised to consider their options carefully, as they might be eligible to recover damages suffered due to alleged misconduct by the company.

Danielle Peyton from Pomerantz Law Firm is the primary contact for affected investors. She can be reached via email at [email protected] or by phone at 646-581-9980. Inquiries via email should include essential details like mailing address, phone number, and the number of REGENXBIO shares purchased.

Critical Deadlines for Investors

April 14, 2026, is a significant date for investors contemplating their legal options. By this deadline, investors are urged to request the court to appoint them as Lead Plaintiff in the class action lawsuit if they purchased REGENXBIO's securities during the specified period. The opportunity for affected individuals to assume this role is essential to ensure that their individual voices are heard within the framework of the class action.

Impact of Recent FDA Holds on REGENXBIO

In January 2026, REGENXBIO faced significant backlash after announcing that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on its investigational gene therapy products, RGX-111 and RGX-121, due to concerning findings related to participant safety in clinical trials. The FDA's decision came after preliminary analysis revealed a case of neoplasm in a participant treated with RGX-111, raising alarms about the safety protocols in place.

As a direct consequence of this announcement, REGENXBIO’s stock price experienced a dramatic drop, falling by $2.40 per share, representing a 17.9% decline. This decline, along with ongoing concerns about the company's operational integrity, adds gravity to the accusations outlined in the class action lawsuit.

Pomerantz Law Firm's Tradition of Advocacy

Founded by the late Abraham L. Pomerantz, a pioneer in the field of securities litigation, the Pomerantz Law Firm has gained recognition for its efforts in securing justice for investors who have faced corporate misconduct. With a legacy spanning over 85 years, the firm prides itself on its commitment to representing victims of securities fraud, breaches of fiduciary duty, and other types of corporate wrongdoing. The firm has earned a reputation for delivering multimillion-dollar damages awards on behalf of its clients and holding corporations accountable for their actions.

Through this class action, the firm seeks to protect the interests of REGENXBIO investors while ensuring that any harmed by the company's alleged wrongdoings have a pathway to recovery.

Conclusion

Investors in REGENXBIO should remain vigilant and take proactive steps to engage with this class action. Given the pivotal deadlines and the potential for recovery under this lawsuit, affected investors have an opportunity to make their voices heard. Those seeking to join the class action are encouraged to reach out to Pomerantz Law Firm without delay to discuss their eligibility and next steps in this significant legal matter.